Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 16/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437012 | 1.00 | USP2 (0.43) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL29437062 | 0.99 | USP2 (0.44) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL26554287 | 0.99 | USP2 (0.44) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL26554279 | 0.98 | STK17B (0.44) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL29437026 | 0.98 | STK17B (0.44) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL26554263 | 0.94 | BCHE (0.46) | USP2LMNABRD4HDAC6 | |
| SCHEMBL26554310 | 0.89 | STK17B (0.44) | USP2LMNABRD4STK17BSTK17A | |
| SCHEMBL31203453 | 0.87 | LMNA (0.48) | USP2LMNAHDAC6 | |
| SCHEMBL26554307 | 0.85 | BCHE (0.46) | USP2LMNABRD4 | |
| SCHEMBL29437071 | 0.84 | LMNA (0.53) | USP2LMNABRD4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | USP2 131/4885LMNA 2726/4885BRD4 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.